New Tech Tackles Gaps in Antibody Discovery
Antibody discovery is a crucial step in the development of biologics, a type of medicine that targets specific cells or proteins in the body. However, the traditional methods used to identify these antibodies have several limitations, leading to failed drug leads and delayed timelines. A new research tool, Lightcast Envisia platform, is poised to revolutionize antibody discovery by providing a non-invasive, real-time view of single cell behavior. This innovative technology has the potential to significantly improve outcomes in early-stage biologic development.
The Challenges of Traditional Antibody Discovery
Antibody discovery typically involves screening a large number of cells or proteins to identify those that bind to a specific target. This process is often time-consuming and costly, and the results can be inconsistent. Traditional methods rely on gene-based screening, which involves inserting a gene of interest into a cell and then using molecular biology techniques to identify the cell’s response. However, this approach has several limitations.
One major challenge is that gene-based screening can only provide a snapshot of a cell’s behavior at a specific point in time. It is unable to capture the dynamic changes that occur within a cell over time, which is critical for understanding the complex interactions between cells and proteins. Additionally, gene-based screening can be prone to errors and false positives, which can lead to the identification of non-functional antibodies.
The Lightcast Envisia Platform
The Lightcast Envisia platform addresses these limitations by using droplet-based microfluidics to capture live cell reactions. This innovative technology allows scientists to observe the behavior of single cells in real-time, providing a more accurate and comprehensive understanding of antibody discovery.
The Envisia platform consists of a microfluidic chip containing thousands of tiny droplets, each containing a single cell. The cells are then exposed to a specific antibody or protein, and the platform uses advanced optics and imaging techniques to capture the cells’ reactions. This allows scientists to observe the binding and unbinding of antibodies to cells, as well as the expression of specific genes and proteins.
Advantages of the Envisia Platform
The Lightcast Envisia platform offers several advantages over traditional gene-based screening methods. One major advantage is its ability to capture live cell reactions in real-time, providing a more accurate and comprehensive understanding of antibody discovery.
The platform is also highly scalable, allowing scientists to screen thousands of cells and antibodies simultaneously. This reduces the time and cost associated with traditional methods, which can require weeks or even months to complete.
Another advantage of the Envisia platform is its ability to identify functional antibodies quickly and efficiently. The platform can detect the binding and unbinding of antibodies to cells, which allows scientists to identify functional antibodies in a matter of days or weeks, rather than months or years.
Impact on Biologic Development
The Lightcast Envisia platform has the potential to significantly improve outcomes in early-stage biologic development. By providing a more accurate and comprehensive understanding of antibody discovery, the platform can help researchers identify functional antibodies more quickly and efficiently.
This can reduce the time and cost associated with biologic development, which can help bring new medicines to market faster and at a lower cost. The platform can also help reduce the number of failed drug leads, which can save millions of dollars and years of research time.
Conclusion
The Lightcast Envisia platform is a game-changing technology that has the potential to revolutionize antibody discovery. By providing a non-invasive, real-time view of single cell behavior, the platform can help researchers identify functional antibodies more quickly and efficiently. This can improve outcomes in early-stage biologic development, reducing the time and cost associated with bringing new medicines to market.
As the biotech industry continues to evolve, it is likely that the Envisia platform will play an increasingly important role in the development of new biologics. With its ability to capture live cell reactions in real-time, the platform offers a powerful tool for researchers seeking to improve the accuracy and efficiency of antibody discovery.
Source:
